In this interview, Omid Hamid, MD, discusses the current landscape of targeted therapies in melanoma. He shares his thoughts about immune response, triplet therapy, and soon-to-be-released data that suggests progression-free survival (PFS) is increased with the use of these targeted therapies. Learn more by clicking here.